Page 157 - Binder2

This pipeline includes:

• Ex vivo Treg induction assays using patient-derived
PBMCs
• Dendritic cell conditioning studies across delivery
platforms
• Cross-species immunogenicity modeling to predict
ADA risks
• Tolerogenic adjuvant screening libraries—co-
formulated and optimized early

Tolerization isn’t treated as a downstream surprise.
It’s treated as a solvable design challenge.

3. Delivery Engineering as an Immune Decision

In most companies, delivery decisions come after
formulation.
They’re based on pharmacokinetics, dosing convenience, or
manufacturing constraints.

In a tolerance-first model, delivery is one of the first
immunological decisions made:

• Oral or mucosal delivery is prioritized where
feasible
• Subcutaneous injections are re-evaluated in light of
local dendritic cell activation risks
• Micro-dosing strategies are tested preclinically for
immune education potential
• Novel encapsulation techniques (e.g., enteric-coated
nanoparticles) are co-developed with the biologic
itself

155